HaemaLogiX

@UCXSwE21maJAgx3YXTeO0VQw - 37 subscribers

HaemaLogiX is a clinical-stage Australian biotechnology company, building a pipeline of immunotherapies to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient's immune system fight their own disease. HaemaLogiX immunotherapies are primarily targeted at multiple myeloma, the world's second most common blood cancer, with over 180,000 new cases globally per year. Sadly there is no cure and 42% of patients will not live more than five years past diagnosis. The company's immunotherapies address the majority of patients who have failed standard of care treatments, offering new treatment options for patients with an incurable disease.